Skip to Content
Merck
CN

I6658

Isradipine

≥98% (HPLC), calcium channel blocker, solid

Synonym(s):

4-(4-Benzofurazanyl)-1,-4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxylic acid methyl 1-methylethyl ester

Sign In to View Organizational & Contract Pricing.

Select a Size

About This Item

Empirical Formula (Hill Notation):
C19H21N3O5
CAS Number:
75695-93-1
Molecular Weight:
371.39
UNSPSC Code:
12352200
PubChem Substance ID:
24724517
NACRES:
NA.77
MDL number:
MFCD00153820

Key Documents

View All Documentation
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

Product Name

Isradipine, ≥98% (HPLC), solid

SMILES string

COC(=O)C1=C(C)NC(C)=C(C1c2cccc3nonc23)C(=O)OC(C)C

InChI key

HMJIYCCIJYRONP-UHFFFAOYSA-N

InChI

1S/C19H21N3O5/c1-9(2)26-19(24)15-11(4)20-10(3)14(18(23)25-5)16(15)12-7-6-8-13-17(12)22-27-21-13/h6-9,16,20H,1-5H3

description

Store under nitrogen

assay

≥98% (HPLC)

form

solid

color

yellow

solubility

DMSO: >10 mg/mL

originator

Novartis

storage temp.

2-8°C

Quality Level

100

Gene Information

human ... CACNA1C(775), CACNA1D(776), CACNA1F(778), CACNA1S(779), CACNA2D1(781)

Looking for similar products? Visit Product Comparison Guide

Related Categories

Application

Isradipine has been used to explore neuroprotective activity.

Biochem/physiol Actions

Isradipine is considered as an active calcium channel blocker, used to treat hypertension.
L-type calcium channel blocker (also referred to as dihydropyridine-type calcium channel blocker); antihypertensive.
L-type calcium channel blocker; antihypertensive.

Features and Benefits

This compound was developed by Novartis. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Storage Class

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

ppe

Eyeshields, Gloves, type N95 (US)

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
079K4708V
0000130120
0000130121
0000114050
0000102826

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

C Savio Chan et al.
Movement disorders : official journal of the Movement Disorder Society, 25 Suppl 1, S63-S70 (2010-02-27)
Parkinson's disease (PD) is a common neurodegenerative disorder of unknown etiology. There is no cure or proven strategy for slowing the progression of the disease. Although there are signs of pathology in many brain regions, the core symptoms of PD
Rodrigo Almeida Simões et al.
Analytical and bioanalytical chemistry, 399(7), 2435-2443 (2011-01-20)
An enantioselective liquid chromatographic method using two-phase hollow fiber liquid-phase microextraction (HF-LPME-HPLC) was developed for the determination of isradipine (ISR) enantiomers and its main metabolite (pyridine derivative of isradipine, PDI) in microsomal fractions isolated from rat liver. The analytes were
Philip F Copenhaver et al.
Disease models & mechanisms, 4(5), 634-648 (2011-05-21)
A growing body of evidence supports the 'calcium hypothesis' of Alzheimer's disease (AD), which postulates that a variety of insults might disrupt the homeostatic regulation of neuronal calcium (Ca(2+)) in the brain, resulting in the progressive symptoms that typify the
Vincent Malaterre et al.
Drug development and industrial pharmacy, 35(4), 433-439 (2008-11-08)
Push-pull osmotic systems have been developed to deliver poorly soluble drugs in a modified-release fashion. The aim of this study was to investigate the influence of the tablet core factors on the drug release kinetics and loadability. The release kinetics
Tanya Simuni et al.
Movement disorders : official journal of the Movement Disorder Society, 25(16), 2863-2866 (2010-09-08)
Recent data suggests that isradipine, a dihydropyridine calcium channel blocker, is neuroprotective in preclinical models of parkinsonism. Isradipine has not been systematically studied in patients with Parkinson's disease (PD). The aim of this study was to evaluate safety and tolerability
View All Related Papers

Related Content

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service